The role of lipid based nanoparticles in brain targeted drug delivery system: An overview

K. Praveen Kumar; P  Nihal; Neeraj Bandari; V. T Iswariya; A. Hari om Prakash Rao; Ritesh Rana; Sumit Kaushik

doi:10.53730/ijhs.v6nS4.8628

Authors

K. Praveen Kumar Govt of NCT Delhi, DPSRU, New Delhi
Nihal. P National College of Pharmacy, Kozhikode, Kerala
Neeraj Bandari Arni School Of Pharmacy, Kangra Himachal Pradesh
V. T Iswariya CMR College of pharmacy, Hyderabad, Telangana
A. Hari om Prakash Rao Research Scholar, Gandhi Nagar, Rushikonda, Visakhapatnam, Andhra Pradesh 530045
Ritesh Rana Himachal Institute of Pharmaceutical Education and Research (HIPER), Bela Nadaun
Sumit Kaushik Faculty of Pharmacy ,Raja Balwant Singh Engineering Technical Campus, Bichpuri, Agra

Keywords:

blood-brain barrier, chemotherapeutic, lipid-based nanoparticles, tumour, Parkinson's disease

Abstract

Recently, targeted drug delivery systems have gained much importance for delivering many kinds of drugs as well as imaging agents, particularly to the targeted disease cells or tissues. The diagnosis and treatment of brain disorders is an extremely challenging task. The blood-brain barrier (BBB) is the primary obstacle in conveying the chemotherapeutic and diagnostic agents that prompt the insufficient delivery of drug at the brain-targeted site. Many drug molecules are non-soluble in aqueous systems, unable to cross BBB, or present severe side effects. Lipid-based nanoparticle (LBNP) systems represent one of the most potential colloidal carriers. They are preferred over polymeric nanoparticles due to their high stability, excellent targeting ability,increased loading capacity, non-toxicity, low production costs, and ease of preparation. Combining drug with lipid nanoparticles reduces the therapeutic dose and toxicity, decreases drug resistance, and increases drug levels in the targeted tissue. This review presents the different types of LBNPs developed in recent years and theirapplication in brain disorders.

Downloads

Download data is not yet available.

References

Abbas H., Refai H., Sayed N., 2018. Superparamagnetic Iron OxideLoaded Lipid Nanocarriers Incorporated in Thermosensitive In Situ Gel for Magnetic Brain Targeting ofClonazepam.Journal Pharmaceutical Science. 107(8):2119-2127.

Ag D., Bongartz R., Dogan LE., 2014. Biofunctional quantum dots as fluorescence probe for cell-specific targeting. Colloids Surf B Biointerfaces. 114: 96-103.

Aparicio-Blanco, J., Romero, I. A., Male, D. K., Slowing, K., García-García, L., and Torres-Suárez, A. I., 2019. Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood–Brain Barrier Both in Vitro and in Vivo. Molecular Pharmaceutics. 16(5), 1999–2010. [doi: 10.1021/acs.molpharmaceut.8b01344]

Bagul U, Pisal V, Solanki N., 2018. Current Status of Solid Lipid Nanoparticles: A Review. Modern Applications of bioequivalence & bioavailability. 3(4) : 1-2.

Bhargava S, Bhargava V., 2018. Surface Modified Solid Lipid Nanoparticles for the targeted delivery to brain: Management of HIV-1 Associated Dementia. International Congress. 880.

Brunn J, Larsen TB, Jolck RI., 2015. Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood–brain barrier. International Journal of Nanomedicine. 10: 5995-6008. [DOI: 10.2147/IJN.S87334]

Chen Y, Pan L, Jiang M, Li D, Jin L., 2016. Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo. Drug Delivery. 23(4): 1383- 92.

Das MK, Palei NN., 2011. Sorbitan ester niosomes for topical delivery of rofecoxib. Indian J Exp Biol. 49(6): 438-45.

De, A., Venkatesh, N., Senthil, M., Sanapalli, B. K. R., Shanmugham, R., & Karri, V. V. S. R., 2018. Smart niosomes of temozolomide for enhancement of brain targeting. Nanobiomedicine. 5, 184954351880535. [doi: 10.1177/1849543518805355]

El Maghraby, G.M., Williams, A.C., 2009. Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin. Expert Opin Drug Deliv. 6(2): 149-63.

Emami J., Rezazadeh M., Sadeghi H., Khadivar K., 2017. Development and optimisation of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design. Pharm Dev Technol. 22(3): 370-82

Estabragh M.A.R.A., ZohrehHamidifar A., Abbas Pardakhty., 2018. Formulation of Rivastigmine Niosomes for Alzheimer Disease. Pharmacy Updates.

Fatouh, A., Elshafeey, A., and Abdelbary, A., 2017. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimisation and in vivo pharmacokinetics. Drug Design, Development and Therapy. Volume 11, 1815–1825. [doi: 10.2147/dddt.s102500]

Gao, H., 2016. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharmaceutica Sinica B. 6(4), 268–286. [doi: 10.1016/j.apsb.2016.05.013]

García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., and López-Romero, J. M., 2019. Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. Nanomaterials. 9(4), 638. [doi: 10.3390/nano9040638]

Hangargekar, S. R., Mohanty, P., and Jain, A., 2019. Solid Lipid Nanoparticles for Brain Targeting. Journal of Drug Delivery and Therapeutics, 9(6-s), 248–252. [doi: 10.22270/jddt.v9i6-s.3783]

Huang FYJ, Lee TW, Chang CH., 2018. Evaluation of 188Relabeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model. Int J Nanomedicine. 10: 463-73

Ishii, T., Asai, T., Oyama, D., Agato, Y., Yasuda, N., Fukuta, T Oku, N., 2013. Treatment of cerebral ischemiareperfusion injury with PEGylated liposomes encapsulating FK506. The FASEB Journal. 27(4), 1362–1370. [doi: 10.1096/fj.12-221325]

Küçüktürkmen, B., Devrim, B., Saka, O.M., Yilmaz, Ş., Arsoy, T., Bozkir, A., 2017. Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells. Drug Dev Ind Pharm. 43(1): 12-21.

Kuo, Y.C., Cheng, S.J., 2016. Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation. International Journal of Pharmaceutics. 499: 10-19. [DOI: 10.1016/j.ijpharm.2015.12.054]

Lakkadwala, S., and Singh, J., 2019. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. Colloids and Surfaces B: Biointerfaces. 173, 27–35. [doi: 10.1016/j.colsurfb.2018.09.047]

Lindqvist, A., Rip, J., Gaillard, P. J., Björkman, S., and Hammarlund-Udenaes, M. 2012. Enhanced Brain Delivery of the Opioid Peptide DAMGO in Glutathione PEGylated Liposomes: A Microdialysis Study. Molecular Pharmaceutics. 10(5), 1533–1541. [doi: 10.1021/mp300272a]

Martins, S.M., Sarmento, B., Nunes, C., 2013. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. European Journal of Pharmaceutics and Biopharmaceutics. 85:488-502. [DOI: 10.1016/j. ejpb.2013.08.011]

Masserini, M., 2013. Nanoparticles for Brain Drug Delivery. ISRN Biochemistry. 2013, 1–18. [doi: 10.1155/2013/238428]

Mohanta, B. C., Dinda, S. C., Palei, N. N., and Deb, J., 2020. Solid Lipid Based Nano-particulate Formulations in Drug Targeting. Role of Novel Drug Delivery Vehicles in Nanobiomedicine. [doi: 10.5772/intechopen.88268]

Mohanta, B. C., Palei, N. N., Surendran, V., Dinda, S. C., Rajangam, J., Deb, J., and Sahoo, B. M., 2019. Lipid Based Nanoparticles: Current Strategies for Brain Tumor Targeting. Current Nanomaterials. 4(2), 84–100. [doi: 10.2174/2405461504666190510121911]

Nasiri, M., Azadi, A., Zanjani, M.R.S., and Hamidi, M., 2019. Indinavir-Loaded Nanostructured Lipid Carriers to Brain Drug Delivery: Optimisation, Characterisation and Neuropharmacokinetic Evaluation. Current Drug Delivery. 16(4), 341–354. [doi: 10.2174/1567201816666190123124429]

Neves A. R., Queiroz, J. F., Reis S., 2016. Braintargeted delivery of resveratrol using solid lipid nanoparticles functionalised with apolipoprotein E. Journal of Nano biotechnology. 14(27):1-11. [DOI: 10.1186/s12951-016-0177-x]

Orthmann, A., Zeisig, R., Süss, R., Lorenz, D., Lemm, M., and Fichtner, I., 2012. Treatment of Experimental Brain Metastasis with MTO-Liposomes: Impact of Fluidity and LRP-Targeting on the Therapeutic Result. Pharmaceutical Research. 29(7), 1949–1959. [doi: 10.1007/s11095-012-0723-7]

Papachristodoulou, A., Signorell, R.D., Werner, B., Brambilla, D., Luciani, P., Cavusoglu, M., Leroux, J.-C., 2019. Chemotherapy sensitisation of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. Journal of Controlled Release. 295, 130–139. [doi: 10.1016/j.jconrel.2018.12.009]

Pardridge, W.M., 2007. Drug targeting to the brain. Pharm Res. 24:1733–44.

Qu, J., Zhang, L., Chen, Z., 2016. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy.Drug Delivery. 23(9): 3408-16.

Ravouru, N., Kondreddy, P., Korakanchi, D., and M., H. 2013. Formulation and Evaluation of Niosomal Nasal Drug Delivery System of Folic Acid for Brain Targeting. Current Drug Discovery Technologies. 10(4), 270–282. [doi: 10.2174/15701638113109990031]

Rodrigues, B.D.S., Oue, H., Banerjee, A., Kanekiyo, T., and Singh, J., 2018. Dual functionalised liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection. Journal of Controlled Release. 286, 264–278. [doi: 10.1016/j.jconrel.2018.07.043]

Roger, M., Clavreul, A., Huynh, N.T., 2012.Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm. 423(1): 63-8.

Rotman, M., Welling, M.M., Bunschoten, A., Backer, M.E.D., Rip, J., Nabuurs, R. J., Weerd, L.V.D., 2015. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimers disease. Journal of Controlled Release. 203, 40–50. [doi: 10.1016/j.jconrel.2015.02.012]

Sita, V., Jadhav, D., and Vavia, P., 2020. Niosomes for nose-to-brain delivery of bromocriptine: Formulation development, efficacy evaluation and toxicity profiling. Journal of Drug Delivery Science and Technology. 58, 101791. [doi: 10.1016/j.jddst.2020.101791]

Sivadasu, P., Gowda, D.V., Subramani, N.K., Vishweshwaraiah, B.M., Shivanna, S., and Hatna, S., 2019. Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterisation and Pharmacokinetic Studies. Indian Journal of Pharmaceutical Education and Research. 54(1), 73–84. [doi: 10.5530/ijper.54.1.9]

Song, S., Mao, G., Du, J., and Zhu, X., 2015. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Delivery. 23(4), 1404–1408. [doi: 10.3109/10717544.2015.1064186]

Teleanu, D., Chircov, C., Grumezescu, A., Volceanov, A., and Teleanu, R., 2018. Blood-Brain Delivery Methods Using Nanotechnology. Pharmaceutics. 10(4), 269. [doi: 10.3390/pharmaceutics10040269]

Wakaskar, R.R., 2018. General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target. 26(4): 311-8.

Wang, J.X., Sun, X., Zhang, Z.R., 2002. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5- fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. European Journal of. Pharmaceutics and Biopharmaceutics. 54 (3) : 285– 290. [doi: 10.1016/s0939-6411(02)00083-8]

Wang, Z., Zhao, Y., Jiang, Y., Lv, W., Wu, L., Wang, B., and Xin, H., 2015. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Scientific Reports. 5(1). [doi: 10.1038/srep12651]

Wolburg, H., Noell, S., Fallier-Becker, P., Mack, A.F., Wolburg-Buchholz, K., 2012. The disturbed blood–brain barrier in human glioblastoma. Mol Aspects Med. 33:579–89

Wu, M., Fan, Y., Lv, S., Xiao, B., Ye, M., Zhu, X., 2016. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 23(8): 2720-5.

Xia, C.F., Boado, R.J., Zhang, Y., Chu, C., and Pardridge, W.M., (2008). Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinsons disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. The Journal of Gene Medicine. 10(3), 306–315. [doi: 10.1002/jgm.1152]

Yasira, B., 2014. Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation, Acta Pharmaceutica Sinica B. 4(6):454–463.

Yingchoncharoen, P., Kalinowski, D.S., Richardson, D.R., 2016. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol. Rev. 68, 701–787.